Evidence map›Paper›PMID 33061671›Full record

ArticleClinical pharmacology : advances and applications2020

Predicted Efficacy of Once-Daily Extended-Release Oxcarbazepine (Oxtellar XR

Shamia Faison, Roberto Gomeni, Shannon Mendes, Welton O'Neal, Stefan Schwabe, Azmi Nasser

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical pharmacology : advances and applications, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Shamia FaisonSupernus Pharmaceuticals, Inc., Rockville, MD, USA.
Roberto GomeniPharmacoMetrica, La Fouillade, France.
Shannon MendesSupernus Pharmaceuticals, Inc., Rockville, MD, USA.ORCID 0000-0002-5939-824X
Welton O'NealSupernus Pharmaceuticals, Inc., Rockville, MD, USA.ORCID 0000-0003-0450-3169
Stefan SchwabeSupernus Pharmaceuticals, Inc., Rockville, MD, USA.
Azmi NasserSupernus Pharmaceuticals, Inc., Rockville, MD, USA.
Supernus Pharmaceuticals (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeWe conducted exposure-response modeling and simulations to compare the predicted efficacy of extended-release oxcarbazepine (OXC-XR), an oral once-daily (qd) antiepileptic drug, with that of immediate-release (IR) OXC twice-daily (bid) when the agents are used as monotherapy or adjunctive therapy in patients with epilepsy characterized by partial-onset seizures (POS).

methodsModeling assessed percent change from baseline 28-day seizure frequency (PCH) as a function of minimum concentration (C

resultsPredicted efficacy was not different (ie, 95% CI of mean PCH overlapped) for OXC-XR qd vs OXC-IR bid at mean MHD C

conclusionThis model-based analysis predicted comparable efficacy for OXC-XR qd vs OXC-IR bid at MHD C

Indexed as

adjunctive therapymonohydroxy derivativemonotherapyoxcarbazepineOxtellar

Identifiers

PMID33061671
PMCPMC7520464
OpenAlexW3088879626

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.